Patent ID: 8329421
Filing Date: 2012-12-11
Classification: A61P,C07K,G01N

Abstract:
1. A method of predicting the response of a neoplasm to an EGFR inhibitor, comprising: contacting a biological sample comprising one or more neoplastic cells with an epidermal growth factor receptor (EGFR) regulatory domain (RD)-antibody or antigen binding fragment thereof that specifically binds to a peptide consisting of amino acid residues 1167-1185 of SEQ ID NO: 1; detecting specific binding of the EGFR RD-antibody or antigen binding fragment thereof to one or more of the neoplastic cells; and determining that the neoplasm will respond to an EGFR inhibitor if specific binding of the EGFR RD-antibody or antigen binding fragment thereof to the one or more neoplastic cells is detected or determining that the neoplastic cells will not substantially respond to an EGFR inhibitor if substantially no specific binding of the EGFR RD-antibody or antigen binding fragment thereof to the EGFR-positive neoplastic cells is detected.